Mach 1 Financial Group LLC Sells 232 Shares of Johnson & Johnson (NYSE:JNJ)

Mach 1 Financial Group LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 9.2% in the 3rd quarter, Holdings Channel reports. The firm owned 2,280 shares of the company’s stock after selling 232 shares during the quarter. Mach 1 Financial Group LLC’s holdings in Johnson & Johnson were worth $370,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $765,000. Duality Advisers LP lifted its position in Johnson & Johnson by 91.6% during the 1st quarter. Duality Advisers LP now owns 43,131 shares of the company’s stock worth $6,823,000 after acquiring an additional 20,615 shares during the last quarter. Empirical Finance LLC boosted its holdings in Johnson & Johnson by 3.2% during the first quarter. Empirical Finance LLC now owns 91,730 shares of the company’s stock valued at $14,511,000 after acquiring an additional 2,883 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in shares of Johnson & Johnson by 11.4% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 125,694 shares of the company’s stock valued at $19,884,000 after purchasing an additional 12,847 shares during the last quarter. Finally, Stokes Family Office LLC increased its stake in shares of Johnson & Johnson by 0.3% in the first quarter. Stokes Family Office LLC now owns 71,297 shares of the company’s stock worth $11,278,000 after purchasing an additional 243 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.47 on Monday. The business has a 50 day simple moving average of $162.61 and a 200 day simple moving average of $155.86. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a market capitalization of $374.31 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the company earned $2.66 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on JNJ shares. Citigroup raised their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim increased their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.